Latest:
Dr Crafton on the Use of Mirvetuximab Soravtansine in Ovarian Cancer
Sarah Crafton, MD, discusses the potential future of antibody-drug conjugates in patients with ovarian cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Sarah E. Hoffe, MD
Latest:
Optimizing Advanced Technologies to Improve Outcomes in Esophageal Cancer
Studies have explored integration of chemotherapy, radiation therapy and surgery, with the suggestion that modern technologies may be changing the treatment landscape with better outcomes in esophageal cancer.
Sarah Ferguson, MD
Latest:
Dr. Ferguson on the Impact of the LACC Trial Data on Cervical Cancer Surgery
Sarah Ferguson, MD, discusses how the results from the LACC trial, which compared minimally invasive surgery with open surgery in patients with IA1, IA2, or IB1 cervical cancer, are impacting surgery in the cervical cancer field.
Sarah Ferguson, MD, FRCSC
Latest:
Dr. Ferguson on Minimally Invasive Vs Open Surgery for Radical Hysterectomy in Cervical Cancer
Sarah Ferguson, MD, FRCSC, discusses the rationale to conduct a population-based cohort study comparing the efficacy of minimally invasive surgery versus open surgery for radical hysterectomy in women with cervical cancer.
Sarah K. Tasian, MD
Latest:
Dr. Tasian on the Heterogeneity of Ph-Like ALL in Pediatric Patients
Sarah K. Tasian, MD, an attending physician and assistant professor of pediatrics in the Division of Oncology at Children’s Hospital of Philadelphia, discusses the heterogeneity of pediatric Philadelphia (Ph)-like acute lymphoblastic leukemia.
Sarah M. C. Sittenfeld, MD
Latest:
Neoadjuvant Radiosurgery Shows Efficacy for Large Brain Metastases
Neoadjuvant stereotactic radiosurgery has gained interest. This approach allows for easier target delineation; a smaller margin of normal brain parenchymal receiving the radiosurgery dose, which may decrease toxicity; and the potential to reduce the risk of leptomeningeal disease by sterilizing the tumor margin preoperatively.
Sarah M. Larson, MD
Latest:
Dr. Larson on the Impact of MRD on Treatment Decisions in Multiple Myeloma
Sarah M. Larson, MD, assistant professor of medicine, and director, Multiple Myeloma Program, University of California, Los Angeles, discusses the impact of minimal residual disease (MRD) on treatment decisions in multiple myeloma.
Sarah Wilcott-Sapp, MD
Latest:
Oncology Surgeons Need Better Training in Palliative Care
It is important for oncology surgeon trainees to learn to recognize when a palliative surgical procedure for an advanced malignancy might be appropriate, be familiar with the conduct of these operations, and understand the nuances of postoperative care and management of complications in this unique patient population.
Sarat Chandarlapaty, MD, PhD
Latest:
Dr. Chandarlapaty on Responses to Amcenestrant/Palbociclib in ER+/HER2- Metastatic Breast Cancer
Sarat Chandarlapaty, MD, PhD, highlights responses to amcenestrant and palbociclib in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer, as seen in the phase 1/2 AMEERA 1 trial.
Saundra Buys, MD
Latest:
Oncologists Must Help Patients Overcome Fear of Genetic Testing to Uncover Cancer Risks
In the current digital age, where all-too-personal information flows from Facebook and Twitter, it seems that the health information available through the process of genetic testing would be an idea welcomed by most of the public.